Source: International Congress 2014 – Asthma and COPD devices and treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Marquez-Martin, F. Ortega Ruiz, E. Campano, C. De la Horra, J. M. Varela, E. Calderón (Seville, Spain). Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD. Eur Respir J 2014; 44: Suppl. 58, 926

Member's Comments

No comment yet.

Related content which might interest you: The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD Source: International Congress 2014 – Translational studies in COPD Year: 2014 A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014